Real-World Evidence Consulting
Expert guidance for regulatory engagements and real-world data study design, led by recognized industry leaders.
Guidance that strengthens every phase of your research
Led by internationally recognized experts, our consulting team brings decades of clinical, epidemiological, and regulatory experience to your research.
Our consultants offer deep expertise across RWD study design, RWE generation, and regulatory submission strategy, working alongside you to ensure every study, submission, and deliverable is compliant, fit-for-purpose, and methodologically sound, and your evidence generation is robust, valid, and actionable.
We can also enhance your market positioning with comprehensive publication and thought leadership support that optimizes your product positioning, market entry strategies, and visibility within the scientific community.
Our RWE consulting services
Explore how we can strengthen every stage of your real-world evidence strategy.
Expert guidance in designing robust and effective real-world data studies.
Strategic support on RWD/RWE use for regulatory engagements and submissions.
Enhance your research visibility and credibility with strategic publication and communications support.
Specialized guidance on selecting the right data sources and developing robust methodologies tailored to your research needs.
Want to learn more?
Explore our related insights
Big data isn’t always the right data. Learn how to assess whether a dataset is truly fit for your research question, because data fitness is about the right elements for the right cohort, not dataset size or reputation.
EHR data is one of the richest sources for real-world research, but it was never actually designed for it. This video covers the opportunities, the pitfalls, and the mindset needed to get the most out of it.
Misaligned definitions don’t just complicate analysis; they produce misleading results. Learn why harmonized definitions are essential for multi-site RWD studies and what it takes to make them stand up to scientific and regulatory scrutiny.
At ISPOR 2026, we presented posters addressing outcomes in relapsed/refractory DLBCL, and introducing a reproducible method for generating population estimates robust enough to stand up in HTA and regulatory submissions.
Contact TriNetX
Need to reach out? We’re here to help.
"*" indicates required fields
